DUBLIN–(BUSINESS WIRE)–The “Dementia – Pipeline Review, H2 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Dementia – Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Dementia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Dementia (Central Nervous System) pipeline guide also reviews the key players involved in therapeutic development for Dementia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 10, 22, 25, 2, 67, 29 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical, Discovery and Unknown stages comprises 1, 1, 12, 5 and 1 molecules, respectively.
Dementia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize the emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Dementia (Central Nervous System).
- Classify potential new clients or partners in the target demographic. (Read more…)
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Dementia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Key Topics Covered:
Introduction
- Dementia – Overview
- Dementia – Therapeutics Development
Dementia – Therapeutics Assessment
Dementia – Companies Involved in Therapeutics Development
Dementia – Drug Profiles
Dementia – Dormant Projects
- Dementia – Discontinued Products
- Dementia – Product Development Milestones
Appendix
Companies Mentioned
- AbbVie Inc
- Acadia Pharmaceuticals Inc
- Actinogen Medical Ltd
- AcuraStem Inc
- Adamed Sp zoo
- ADEL Inc
- AFFiRiS AG
- AgeneBio Inc
- Aibios Co Ltd
- Alector Inc
- Alkermes Plc
- Allergan Ltd
- AlphaCognition Inc
- Alterity Therapeutics Ltd
- Anavex Life Sciences Corp
- Annovis Bio Inc
- Applied Genetic Technologies Corp
- Aprinoia Therapeutics Inc
- AriBio
- Arkuda Therapeutics Inc
- Arvinas Inc
- Asceneuron SA
- Avanir Pharmaceuticals Inc
- Axon Neuroscience SE
- Axovant Gene Therapies Ltd
- Axsome Therapeutics Inc
- Bicycle Therapeutics Plc
- Biogen Inc
- BioXcel Therapeutics Inc
- Boehringer Ingelheim International GmbH
- Cellular Biomedicine Group Ltd
- Cennerv Pharma (S) Pte Ltd
- Cerevel Therapeutics LLC
- ChunLab Inc
- Cortice Biosciences Inc
- CSPC NBP Pharmaceutical Co Ltd
- Curyx Bio Inc
- Cyclerion Therapeutics Inc
- Dadang & BIO Co Ltd
- Daewoong Pharmaceutical Co Ltd
- Denali Therapeutics Inc
- DiaMedica Therapeutics Inc
- Dongkook Pharmaceutical Co Ltd
- Dr. August Wolff GmbH & Co KG Arzneimittel
- Echo Pharmaceuticals BV
- EIP Pharma LLC
- Eisai Co Ltd
- Eli Lilly and Co
- Ensol Biosciences Inc
- Enterin Inc
- EVER Neuro Pharma GmbH
- Galimedix Therapeutics Ltd
- Gismo Therapeutics Inc
- Guangzhou Magpie Pharmaceutical Co Ltd
- GW Pharmaceuticals Plc
- HanAll Biopharma Co Ltd
- Hemostemix Inc
- HSRx Group
- Hyundai Pharma Co Ltd
- Immungenetics AG
- ImStar Therapeutics Inc
- Inhibikase Therapeutics Inc
- IntraBio Ltd
- IRLAB Therapeutics AB
- Johnson & Johnson
- Kogenix Therapeutics Inc
- Korea Pharma Co Ltd
- Kwang Dong Pharmaceutical Co Ltd
- Lachesis Biosciences Ltd
- Luye Pharma Group Ltd
- Mediforum Pharmaceutical Inc
- MediPost Co Ltd
- Merck & Co Inc
- Merz Pharma GmbH & Co KgaA
- MGC Pharmaceuticals Ltd
- Neuraltus Pharmaceuticals Inc
- Neurimmune Holding AG
- Neurokine Therapeutics
- NeuroScientific Biopharmaceuticals Ltd
- NeuroTau Inc
- NLS Pharma Group
- Novartis AG
- Oligomerix inc
- Orchard Therapeutics Plc
- Oryzon Genomics SA
- Otsuka Pharmaceutical Co Ltd
- P2D Inc
- Pacific Northwest Biotechnology LLC
- Palisades Therapeutics
- Park Active Molecules
- Passage Bio Inc
- Plico Biotech Inc
- Prediction BioSciences SAS
- Prevail Therapeutics Inc
- ProMIS Neurosciences Inc
- Prothena Corp Plc
- Psy Therapeutics Inc
- QurAlis Corporation
- Reborna Biosciences Inc
- Resverlogix Corp
- Reven Pharmaceuticals Inc
- Samus Therapeutics Inc
- Sinfonia Biotherapeutics Inc
- SK Chemicals Co Ltd
- Stemedica Cell Technologies Inc
- Sun Pharma Advanced Research Company Ltd
- Suven Life Sciences Ltd
- SyneuRx International Corp
- T3D Therapeutics Inc
- TauRx Therapeutics Ltd
- Theranexus SAS
- Time Therapeutics Inc
- Towa Pharmaceutical Co Ltd
- Tranquis Therapeutics Inc
- UniQure NV
- Verge Genomics Inc
- Voyager Therapeutics Inc
- Wave Life Sciences Ltd
- WhanIn Pharmaceutical Co Ltd
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/urlcg1
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900